This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
The lancet. Gastroenterology & hepatology, 8(6), 511-522
Citation
Loomba, Rohit; Abdelmalek, Manal F; Armstrong, Matthew J; Jara, Maximilian; Kjær, Mette Skalshøi; Krarup, Niels; Lawitz, Eric; Ratziu, Vlad; Sanyal, Arun J; Schattenberg, Jörn M; Newsome, Philip N. (2023). Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.. The lancet. Gastroenterology & hepatology, 8(6), 511-522. https://doi.org/10.1016/S2468-1253(23)00068-7